한글목차

화이자(Pfizer)가 개발한 PF-06823859는 중등도에서 중증의 피부근육염 및 루푸스 치료제로 현재 임상 2상 개발 단계에 있습니다. 이 신약 후보물질은 신규 생물학적 제제(NBE)로 분류되며, 인간화 면역글로불린 중화항체입니다. 이 약은 정맥 및 근육 주사로 투여되며, 이들 질환의 병인에 관여하는 중요한 사이토카인인 인터페론 베타 1(IFNB1)을 특이적으로 표적화하여 작용합니다.

본 보고서는 미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국, 일본 등 주요 7개국의 염증성 근염(IM) 치료제 PF-06823859에 대한 2019년부터 2032년까지 상세한 현황과 IM 치료제 PF-06823859에 대한 자세한 설명을 함께 게재하고 있습니다. 또한 작용기전, 용법 및 용량, 규제 마일스톤을 포함한 연구개발 및 기타 개발 활동에 대한 인사이트를 제공합니다. 또한 주요 7개국에서 IM의 PF-06823859 시장 예측 분석, SWOT, 애널리스트의 견해, 시장 경쟁사 개요, IM의 다른 신흥 치료제에 대한 개요 등 향후 시장 평가도 포함돼 있습니다.

목차

제1장 보고서 소개

제2장 염증성 근염(IM)의 PF-06823859 개요

• 제품 상세
• 임상 개발
• 기타 발달 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료법)

제4장 경쟁 구도(후기 단계 새로운 치료법)

제5장 PF-06823859 시장 평가

• 염증성 근염(IM)의 PF-06823859 시장 전망
• 주요 7개국 분석
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 보고서 구입 옵션

영문목차

"PF-06823859 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about PF-06823859 for Inflammatory Myositis (IM) in the seven major markets. A detailed picture of the PF-06823859 for IM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the PF-06823859 for IM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PF-06823859 market forecast analysis for IM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in IM.

Drug Summary:

PF-06823859, an investigational drug developed by Pfizer, is currently in Phase II developmental stages as a potential treatment for moderate-to-severe dermatomyositis and lupus. This drug candidate is categorized as a new biological entity (NBE) and is a humanized immunoglobulin-neutralizing antibody. It is administered via IV and SC injection and works by specifically targeting interferon beta 1 (IFNB1), a key cytokine involved in the pathogenesis of these diseases.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the PF-06823859 description, mechanism of action, dosage and administration, research and development activities in Inflammatory Myositis (IM).
• Elaborated details on PF-06823859 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the PF-06823859 research and development activities in IM across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around PF-06823859.
• The report contains forecasted sales of PF-06823859 for IM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for IM.
• The report also features the SWOT analysis with analyst views for PF-06823859 in IM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PF-06823859 Analytical Perspective by DelveInsight

• In-depth PF-06823859 Market Assessment

This report provides a detailed market assessment of PF-06823859 for Inflammatory Myositis (IM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• PF-06823859 Clinical Assessment

The report provides the clinical trials information of PF-06823859 for Inflammatory Myositis (IM) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Inflammatory Myositis (IM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PF-06823859 dominance.
• Other emerging products for IM are expected to give tough market competition to PF-06823859 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PF-06823859 in IM.
• Our in-depth analysis of the forecasted sales data of PF-06823859 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PF-06823859 in IM.

Key Questions:

• What is the product type, route of administration and mechanism of action of PF-06823859?
• What is the clinical trial status of the study related to PF-06823859 in Inflammatory Myositis (IM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PF-06823859 development?
• What are the key designations that have been granted to PF-06823859 for IM?
• What is the forecasted market scenario of PF-06823859 for IM?
• What are the forecasted sales of PF-06823859 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to PF-06823859 for IM?
• Which are the late-stage emerging therapies under development for the treatment of IM?

Table of Contents

1. Report Introduction

2. PF-06823859 Overview in Inflammatory Myositis (IM)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. PF-06823859 Market Assessment

• 5.1. Market Outlook of PF-06823859 in Inflammatory Myositis (IM)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of PF-06823859 in the 7MM for Inflammatory Myositis (IM)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of PF-06823859 in the United States for Inflammatory Myositis (IM)
  • 5.3.2. Market Size of PF-06823859 in Germany for Inflammatory Myositis (IM)
  • 5.3.3. Market Size of PF-06823859 in France for Inflammatory Myositis (IM)
  • 5.3.4. Market Size of PF-06823859 in Italy for Inflammatory Myositis (IM)
  • 5.3.5. Market Size of PF-06823859 in Spain for Inflammatory Myositis (IM)
  • 5.3.6. Market Size of PF-06823859 in the United Kingdom for Inflammatory Myositis (IM)
  • 5.3.7. Market Size of PF-06823859 in Japan for Inflammatory Myositis (IM)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options